|
MechanismmAChRs antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date20 Jul 1968 |
硫酸阿托品滴眼液(不同浓度)延缓儿童近视进展的有效性和安全性的随机、双盲、安慰剂对照、多中心Ⅱ/Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II/III clinical trial on the efficacy and safety of atropine sulfate eye drops (different concentrations) in delaying the progression of myopia in children
评价不同浓度的硫酸阿托品滴眼液与安慰剂相比延缓儿童近视进展的疗效
[Translation] To evaluate the efficacy of different concentrations of atropine sulfate eye drops compared with placebo in delaying the progression of myopia in children
在中国健康成人受试者中考察硫酸阿托品滴眼液的安全性、耐受性、药代动力学的I期临床研究
[Translation] A phase I clinical study to investigate the safety, tolerability, and pharmacokinetics of atropine sulfate eye drops in healthy Chinese adult subjects
(1)评估多次使用硫酸阿托品滴眼液在健康成人受试者中的安全性和耐受性;
(2)评估多次使用硫酸阿托品滴眼液在健康成人受试者中的药代动力学特征;
(3)确定预计有效剂量下的耐受性和药代动力学特征,为后续临床试验推荐合适的给药浓度和方案
[Translation] (1) Evaluate the safety and tolerability of multiple doses of atropine sulfate eye drops in healthy adult subjects;
(2) Evaluate the pharmacokinetic characteristics of multiple doses of atropine sulfate eye drops in healthy adult subjects;
(3) Determine the tolerability and pharmacokinetic characteristics at the expected effective dose and recommend appropriate dosing concentrations and regimens for subsequent clinical trials
100 Clinical Results associated with Hangzhou Hels Technology Co., Ltd.
0 Patents (Medical) associated with Hangzhou Hels Technology Co., Ltd.
100 Deals associated with Hangzhou Hels Technology Co., Ltd.
100 Translational Medicine associated with Hangzhou Hels Technology Co., Ltd.